Lactobacillus reuteri for Infants with Colic: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial
- 29 September 2017
- journal article
- research article
- Published by Elsevier BV in The Journal of Pediatrics
- Vol. 191, 170-178.e2
- https://doi.org/10.1016/j.jpeds.2017.07.036
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- 454 Pyrosequencing Analysis on Faecal Samples from a Randomized DBPC Trial of Colicky Infants Treated with Lactobacillus reuteri DSM 17938PLOS ONE, 2013
- Lactobacillus reuteri DSM 17938 Changes the Frequency of Foxp3+ Regulatory T Cells in the Intestine and Mesenteric Lymph Node in Experimental Necrotizing EnterocolitisPLOS ONE, 2013
- Safety and Tolerability of Lactobacillus reuteri DSM 17938 and Effects on Biomarkers in Healthy Adults: Results from a Randomized Masked TrialPLOS ONE, 2012
- Helios Expression Is a Marker of T Cell Activation and ProliferationPLOS ONE, 2011
- Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammationAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2010
- QIIME allows analysis of high-throughput community sequencing dataNature Methods, 2010
- Expression of Helios, an Ikaros Transcription Factor Family Member, Differentiates Thymic-Derived from Peripherally Induced Foxp3+ T Regulatory CellsThe Journal of Immunology, 2010
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2008
- Safety of probiotics: comparison of two popular strainsBMJ, 2006
- Breath hydrogen response to milk containing lactose in colicky and noncolicky infantsThe Journal of Pediatrics, 1988